Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
Therapeutic Advances in Medical Oncology
|
April 26, 2019
Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine
Femke M de Man, G D Marijn Veerman, Esther Oomen-de Hoop, et al.
British Journal of Cancer
|
April 21, 2017
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
Didier Meulendijks, Linda M Henricks, Bart A W Jacobs, et al.
International Journal of Cancer
|
June 19, 2025
Real-world study on fluoropyrimidine-related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype-guided dosing
Sofía L J Peeters, Didier Meulendijks, Zerina Kadric, et al.
British Journal of Clinical Pharmacology
|
May 11, 2016
Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers
Bart A W Jacobs, Maarten J Deenen, Dick Pluim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Joyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2014
A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers
Ulrik N Lassen, Didier Meulendijks, Lilian L Siu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors
Didier Meulendijks, Ulrik N Lassen, Lillian L Siu, et al.
Investigational New Drugs
|
December 9, 2015
Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study
Didier Meulendijks, Laurens V Beerepoot, Henk Boot, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 13, 2021
Prognostic value of high-risk human papillomavirus DNA and p16<sup>INK4a</sup> immunohistochemistry in patients with anal cancer: An individual patient data meta-analysis
Theresa Obermueller, Joris Hautekiet, Maria P Busto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2015
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
Didier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
Therapeutic Advances in Medical Oncology
|
April 26, 2019
Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine
Femke M de Man, G D Marijn Veerman, Esther Oomen-de Hoop, et al.
British Journal of Cancer
|
April 21, 2017
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
Didier Meulendijks, Linda M Henricks, Bart A W Jacobs, et al.
International Journal of Cancer
|
June 19, 2025
Real-world study on fluoropyrimidine-related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype-guided dosing
Sofía L J Peeters, Didier Meulendijks, Zerina Kadric, et al.
British Journal of Clinical Pharmacology
|
May 11, 2016
Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers
Bart A W Jacobs, Maarten J Deenen, Dick Pluim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Joyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2014
A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers
Ulrik N Lassen, Didier Meulendijks, Lilian L Siu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors
Didier Meulendijks, Ulrik N Lassen, Lillian L Siu, et al.
Investigational New Drugs
|
December 9, 2015
Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study
Didier Meulendijks, Laurens V Beerepoot, Henk Boot, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 13, 2021
Prognostic value of high-risk human papillomavirus DNA and p16<sup>INK4a</sup> immunohistochemistry in patients with anal cancer: An individual patient data meta-analysis
Theresa Obermueller, Joris Hautekiet, Maria P Busto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2015
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
Didier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, et al.
Page
of 5